Tumor Lysis Syndrome

 

 Buy Article Permissions and Reprints

ABSTRACT

Tumor lysis syndrome (TLS) is an important metabolic disorder frequently encountered in the management of a variety of cancers including lymphoma, leukemia, and neuroblastoma. Delayed recognition can result in a variety of biochemical abnormalities resulting in life-threatening complications such as renal failure, arrhythmias, and seizures. Identification of high-risk patients and early recognition of the syndrome is crucial in the early institution of appropriate prophylaxis and treatment. Recent advances in the understanding of urate metabolism, development of new urate-lowering drugs, and the application of biomarkers, calculation methods, and prognostic models to identify high-risk patients will pave the way in improving the management of TLS. We included in this review the new information regarding the urate transporters URAT-1, organic anion transporter 1/3, and MRP4; the urate elimination pathway; a comparison of the old- (allopurinol, native uricase) and new- (febuxostat, Y-700, PEG-uricase, rasburicase) generation urate-lowering agents; and application of new biomarkers (cystatin-C, neutrophil gelatinase-associated lipocalin, kidney injury molecule 1), estimated glomerular filtration rate and calculation methods (modification of diet in renal disease and prognostic model (Penn Predictive Score of Tumor Lysis Syndrome) in the identification of high-risk patients, and alternative unexplored mechanisms (asymmetric dimethylarginine and adenosine) to explain renal injury related to TLS.

REFERENCES

• 1 Beriwal S, Singh S, Garcia-Young J A. Tumor lysis syndrome in extensive-stage small-cell lung cancer.  Am J Clin Oncol. 2002;  25 474-475
  CrossrefPubMedGoogle Scholar
• 2 Khan J, Broadbent V A. Tumor lysis syndrome complicating treatment of widespread metastatic abdominal rhabdomyosarcoma.  Pediatr Hematol Oncol. 1993;  10 151-155
  PubMedGoogle Scholar
• 3 Kushner B H, LaQuaglia M P, Modak S, Cheung N K. Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification.  Med Pediatr Oncol. 2003;  41 80-82
  CrossrefPubMedGoogle Scholar
• 4 Bedrna J, Polcák J. Akuter Harnleiterverschluss nach Bestrahlung chronischer Leukämien mit Röntgenstrahlen.  Med Klin. 1929;  25 1700-1701
  PubMedGoogle Scholar
• 5 Crittenden D R, Ackerman G L. Hyperuricemic acute renal failure in disseminated carcinoma.  Arch Intern Med. 1977;  137 97-99
  CrossrefPubMedGoogle Scholar
• 6 Persons D A, Garst J, Vollmer R, Crawford J. Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.  Am J Clin Oncol. 1998;  21 426-429
  CrossrefPubMedGoogle Scholar
• 7 Benekli M, Gullu I H, Savas M C et al.. Acute tumor lysis syndrome following intrathecal methotrexate.  Leuk Lymphoma. 1996;  22 361-363
  PubMedGoogle Scholar
• 8 Frame J N, Dahut W L, Crowley S. Fludarabine and acute tumor lysis in chronic lymphocytic leukemia.  N Engl J Med. 1992;  327 1396-1397
  PubMedGoogle Scholar
• 9 Abou Mourad Y, Taher A, Shamseddine A. Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20.  Hematol J. 2003;  4 222-224
  CrossrefPubMedGoogle Scholar
• 10 Fleming D R, Henslee-Downey P J, Coffey C W. Radiation induced acute tumor lysis syndrome in the bone marrow transplant setting.  Bone Marrow Transplant. 1991;  8 235-236
  PubMedGoogle Scholar
• 11 Dhingra K, Newcom S R. Acute tumor lysis syndrome in non-Hodgkin lymphoma induced by dexamethasone.  Am J Hematol. 1988;  29 115-116
  CrossrefPubMedGoogle Scholar
• 12 Jasek A M, Day H J. Acute spontaneous tumor lysis syndrome.  Am J Hematol. 1994;  47 129-131
  CrossrefPubMedGoogle Scholar
• 13 Fenaux P, Lai J L, Miaux O et al.. Burkitt cell acute leukaemia (L3 ALL) in adults: a report of 18 cases.  Br J Haematol. 1989;  71 371-376
  PubMedGoogle Scholar
• 14 Seftel M D, Bruyere H, Copland M et al.. Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).  Eur J Haematol. 2002;  69 193-199
  CrossrefPubMedGoogle Scholar
• 15 Ichida K, Hosoyamada M, Hisatome I et al.. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion.  J Am Soc Nephrol. 2004;  15 164-173
  CrossrefPubMedGoogle Scholar
• 16 Jutabha P, Kanai Y, Hosoyamada M. at al. Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule.  J Biol Chem. 2003;  278 27930-27938
  CrossrefPubMedGoogle Scholar
• 17 Van Aubel R A, Smeets P H, van den Heuvel J J, Russel F G. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.  Am J Physiol Renal Physiol. 2005;  288 F327-F333
  PubMedGoogle Scholar
• 18 Lipkowitz M S, Leal-Pinto E, Rappoport J Z, Najfeld V, Abramson R G. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter.  J Clin Invest. 2001;  107 1103-1115
  PubMedGoogle Scholar
• 19 Enomoto A, Kimura H, Chairoungdua A et al.. Molecular identification of a renal urate anion exchanger that regulates blood urate levels.  Nature. 2002;  417 447-452
  PubMedGoogle Scholar
• 20 Hosoyamada M, Ichida K, Enomoto A, Hosoya T, Endou H. Function and localization of urate transporter 1 in mouse kidney.  J Am Soc Nephrol. 2004;  15 261-268
  CrossrefPubMedGoogle Scholar
• 21 Hosoyamada M, Sekine T, Kanai Y, Endou H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney.  Am J Physiol. 1999;  276(1 pt 2) F122-F128
  PubMedGoogle Scholar
• 22 Xu G, Bhatnagar V, Wen G et al.. Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes. [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)].  Kidney Int. 2005;  68 1491-1499
  CrossrefPubMedGoogle Scholar
• 23 Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications.  Mol Biol Evol. 2002;  19 640-653
  CrossrefPubMedGoogle Scholar
• 24 Ramazzina I, Folli C, Secchi A, Berni R, Percudani R. Completing the uric acid degradation pathway through phylogenetic comparison of whole genomes.  Nat Chem Biol. 2006;  2 144-148
  CrossrefPubMedGoogle Scholar
• 25 Cairo M S, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification.  Br J Haematol. 2004;  127 3-11
  CrossrefPubMedGoogle Scholar
• 26 Mandal A K. Hypokalemia and hyperkalemia.  Med Clin North Am. 1997;  81 611-639
  CrossrefPubMedGoogle Scholar
• 27 Overgaard K, Nielsen O B, Clausen T. Effects of reduced electrochemical Na + gradient on contractility in skeletal muscle: role of the Na⁺-K⁺ pump.  Pflugers Arch. 1997;  434 457-465
  PubMedGoogle Scholar
• 28 Davidson M B, Thakkar S, Hix J K et al.. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.  Am J Med. 2004;  116 546-554
  CrossrefPubMedGoogle Scholar
• 29 Mato A R, Riccio B E, Qin L et al.. A predictive model for the detection of tumor lysis syndrome during AML induction therapy.  Leuk Lymphoma. 2006;  47 877-883
  CrossrefPubMedGoogle Scholar
• 30 Arrambide K, Toto R D. Tumor lysis syndrome.  Semin Nephrol. 1993;  13 273-280
  PubMedGoogle Scholar
• 31 Watts R W, Watts J E, Seegmiller J E. Xanthine oxidase activity in human tissues and its inhibition by allopurinol (4-hydroxypyrazolo[3,4-d] pyrimidine).  J Lab Clin Med. 1965t;  66 688-697
  PubMedGoogle Scholar
• 32 DeConti R C, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease.  N Engl J Med. 1966;  274 481-486
  CrossrefPubMedGoogle Scholar
• 33 Becker M A, Schumacher Jr H R, Wortmann R L et al.. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.  N Engl J Med. 2005;  353 2450-2461
  CrossrefPubMedGoogle Scholar
• 34 Becker M A, Kisicki J, Khosravan R et al.. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.  Nucleosides Nucleotides Nucleic Acids. 2004;  23 1111-1116
  CrossrefPubMedGoogle Scholar
• 35 Yamada I, Fukunari A, Osajima T et al.. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man.  Nucleosides Nucleotides Nucleic Acids. 2004;  23 1123-1125
  CrossrefPubMedGoogle Scholar
• 36 Fukunari A, Okamoto K, Nishino T et al.. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.  J Pharmacol Exp Ther. 2004;  311 519-528
  CrossrefPubMedGoogle Scholar
• 37 Mayer M D, Khosravan R, Vernillet L et al.. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.  Am J Ther. 2005;  12 22-34
  CrossrefPubMedGoogle Scholar
• 38 Chanteclair G, Olive D. Acute hyperuricemic kidney failure. Treatment by uricozyme.  Nouv Presse Med. 1975;  4 2274
  PubMedGoogle Scholar
• 39 Masera G, Jankovic M, Zurlo M G et al.. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia.  J Pediatr. 1982;  100 152-155
  PubMedGoogle Scholar
• 40 Pui C H, Mahmoud H H, Wiley J M et al.. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma.  J Clin Oncol. 2001;  19 697-704
  PubMedGoogle Scholar
• 41 Davis S, Park Y K, Abuchowski A, Davis F F. Hypouricaemic effect of polyethyleneglycol modified urate oxidase.  Lancet. 1981;  2 281-283
  PubMedGoogle Scholar
• 42 Savoca K V, Davis F F, Palczuk N C. Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.  Int Arch Allergy Appl Immunol. 1984;  75 58-67
  PubMedGoogle Scholar
• 43 Chua C C, Greenberg M L, Viau A T et al.. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.  Ann Intern Med. 1988;  109 114-117
  PubMedGoogle Scholar
• 44 Bomalaski J S, Holtsberg F W, Ensor C M, Clark M A. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.  J Rheumatol. 2002;  29 1942-1949
  PubMedGoogle Scholar
• 45 Briglia A E. The current state of nonuremic applications for extracorporeal blood purification.  Semin Dial. 2005;  18 380-390
  CrossrefPubMedGoogle Scholar
• 46 Schelling J R, Ghandour F Z, Strickland T J, Sedor J R. Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature.  Ren Fail. 1998;  20 635-644
  PubMedGoogle Scholar
• 47 Procaccini D A, Querques M, Tappi A, Strippoli P. Peritoneal clearances. Long-term study.  ASAIO Trans. 1988;  34 437-440
  PubMedGoogle Scholar
• 48 Descombes E, Perriard F, Fellay G. Diffusion kinetics of urea, creatinine and uric acid in blood during hemodialysis. Clinical implications.  Clin Nephrol. 1993;  40 286-295
  PubMedGoogle Scholar
• 49 Levey A S, Bosch J P, Lewis J B et al.. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.  Ann Intern Med. 1999;  130 461-470
  PubMedGoogle Scholar
• 50 Lamb E J, Stowe H J, Simpson D E et al.. Diagnostic accuracy of cystatin C as a marker of kidney disease in patients with multiple myeloma: calculated glomerular filtration rate formulas are equally useful.  Clin Chem. 2004;  50 1848-1851
  CrossrefPubMedGoogle Scholar
• 51 Verhave J C, Fesler P, Ribstein J, du Cailar G, Mimran A. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index.  Am J Kidney Dis. 2005;  46 233-241
  CrossrefPubMedGoogle Scholar
• 52 Poggio E D, Wang X, Greene T, Van Lente F, Hall P M. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease.  J Am Soc Nephrol. 2005;  16 459-466
  CrossrefPubMedGoogle Scholar
• 53 Kopple J D, Berg R, Houser H, Steinman T I, Teschan P. Nutritional status of patients with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease (MDRD) Study Group.  Kidney Int. 1989;  27(suppl) S184-S194
  PubMedGoogle Scholar
• 54 Menon V, Wang X, Greene T et al.. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease.  Am J Kidney Dis. 2003;  42 44-52
  CrossrefPubMedGoogle Scholar
• 55 Poge U, Gerhardt T, Stoffel-Wagner B et al.. Prediction of glomerular filtration rate in renal transplant recipients: cystatin C or modification of diet in renal disease equation?.  Clin Transplant. 2006;  20 200-205
  CrossrefPubMedGoogle Scholar
• 56 Madero M, Sarnak M J, Stevens L A. Serum cystatin C as a marker of glomerular filtration rate.  Curr Opin Nephrol Hypertens. 2006;  15 610-616
  PubMedGoogle Scholar
• 57 Seronie-Vivien S, Toullec S, Malard L et al.. Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients.  Med Oncol. 2006;  23 63-73
  CrossrefPubMedGoogle Scholar
• 58 Thomas F, Seronie-Vivien S, Gladieff L et al.. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin.  Clin Pharmacokinet. 2005;  44 1305-1316
  CrossrefPubMedGoogle Scholar
• 59 Hoppe A, Seronie-Vivien S, Thomas F et al.. Serum cystatin C is a better marker of topotecan clearance than serum creatinine.  Clin Cancer Res. 2005;  11 3038-3044
  CrossrefPubMedGoogle Scholar
• 60 Mishra J, Ma Q, Prada A et al.. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury.  J Am Soc Nephrol. 2003;  14 2534-2543
  CrossrefPubMedGoogle Scholar
• 61 Han W K, Alinani A, Wu C L et al.. Human kidney injury molecule-1 is a tissue and urinary rumor marker of renal carcinoma.  J Am Soc Nephrol. 2005;  16 1126-1134
  CrossrefPubMedGoogle Scholar
• 62 Matsuguma K, Ueda S, Yamagishi S et al.. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.  J Am Soc Nephrol. 2006;  17 2176-2183
  CrossrefPubMedGoogle Scholar
• 63 Busch M, Fleck C, Wolf G, Stein G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease-possible candidates for paradoxical epidemiology?.  Amino Acids. 2006;  30 225-232
  CrossrefPubMedGoogle Scholar
• 64 Kielstein J T, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans.  Eur J Clin Pharmacol. 2006;  62(suppl 13) 39-44
  CrossrefPubMedGoogle Scholar
• 65 Siroka R, Trefil L, Rajdl D et al.. Asymmetric dimethylarginine, homocysteine and renal function-is there a relation?.  Clin Chem Lab Med. 2005;  43 1147-1150
  CrossrefPubMedGoogle Scholar
• 66 Kawamoto R, Tomita H, Oka Y, Ohtsuka N. Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis.  Intern Med. 2006;  45 605-614
  CrossrefPubMedGoogle Scholar
• 67 Sanchez-Lozada L G, Nakagawa T, Kang D H et al.. Hormonal and cytokine effects of uric acid.  Curr Opin Nephrol Hypertens. 2006;  15 30-33
  PubMedGoogle Scholar
• 68 Sanchez-Lozada L G, Tapia E, Santamaria J et al.. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats.  Kidney Int. 2005;  67 237-247
  CrossrefPubMedGoogle Scholar
• 69 Weyler S, Fulle F, Diekmann M et al.. Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd] purinediones.  ChemMedChem. 2006;  1(8) 891-902
  CrossrefPubMedGoogle Scholar
• 70 Osswald H, Schmitz H J, Kemper R. Tissue content of adenosine, inosine and hypoxanthine in the rat kidney after ischemia and postischemic recirculation.  Pflugers Arch. 1977;  371 45-49
  CrossrefPubMedGoogle Scholar
• 71 Nishiyama A, Miyatake A, Aki Y et al.. Adenosine A(1) receptor antagonist KW-3902 prevents hypoxia-induced renal vasoconstriction.  J Pharmacol Exp Ther. 1999;  291 988-993
  PubMedGoogle Scholar
• 72 Yao K, Kusaka H, Sato K, Karasawa A. Protective effects of KW-3902, a novel adenosine A1-receptor antagonist, against gentamicin-induced acute renal failure in rats.  Jpn J Pharmacol. 1994;  65 167-170
  PubMedGoogle Scholar
• 73 Yao K, Heyne N, Erley C M, Risler T, Osswald H. The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency.  Eur J Pharmacol. 2001;  414 99-104
  CrossrefPubMedGoogle Scholar

Martin J Schreiber Jr.M.D. 

Department of Nephrology and Hypertension, Cleveland Clinic

9500 Euclid Avenue, Desk A51, Cleveland, Ohio 44195

Email: schreim@ccf.org